7 results on '"Napolitano, Maria"'
Search Results
2. Prospective Evaluation of Radiotherapy-Induced Immunologic and Genetic Effects in Colorectal Cancer Oligo-Metastatic Patients with Lung-Limited Disease: The PRELUDE-1 Study
- Author
-
Ottaiano, Alessandro, primary, Petito, Angela, additional, Santorsola, Mariachiara, additional, Gigantino, Valerio, additional, Capuozzo, Maurizio, additional, Fontanella, Daniela, additional, Di Franco, Rossella, additional, Borzillo, Valentina, additional, Buonopane, Sergio, additional, Ravo, Vincenzo, additional, Scipilliti, Esmeralda, additional, Totaro, Giuseppe, additional, Serra, Marcello, additional, Ametrano, Gianluca, additional, Penta, Roberta, additional, Tatangelo, Fabiana, additional, Scognamiglio, Giosuè, additional, Di Mauro, Annabella, additional, Di Bonito, Maurizio, additional, Napolitano, Maria, additional, Scala, Stefania, additional, Rea, Giuseppina, additional, Santagata, Sara, additional, Lombardi, Angela, additional, Grimaldi, Anna, additional, Caputo, Carlo, additional, Crispo, Anna, additional, Celentano, Egidio, additional, De Feo, Gianfranco, additional, Circelli, Luisa, additional, Savarese, Giovanni, additional, Ruggiero, Raffaella, additional, Perri, Francesco, additional, Granata, Vincenza, additional, Botti, Gerardo, additional, Caraglia, Michele, additional, Nasti, Guglielmo, additional, and Muto, Paolo, additional
- Published
- 2021
- Full Text
- View/download PDF
3. Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients.
- Author
-
D'Alterio, Crescenzo, Spina, Anna, Arenare, Laura, Chiodini, Paolo, Napolitano, Maria, Galdiero, Francesca, Portella, Luigi, Simeon, Vittorio, Signoriello, Simona, Raspagliesi, Francesco, Lorusso, Domenica, Pisano, Carmela, Colombo, Nicoletta, Zannoni, Gian Franco, Losito, Nunzia Simona, De Cecio, Rossella, Scognamiglio, Giosuè, Califano, Daniela, Russo, Daniela, and Tuninetti, Valentina
- Subjects
OVARIAN tumors ,STROMAL cells ,CANCER patients ,TUMOR markers - Abstract
Simple Summary: Despite rapid progress in the research on epithelial ovarian cancer (EOC), it is usually diagnosed during the advanced stage with only 30% of patients surviving longer than 5 years. This is the first study in which the whole CXCR4-CXCL12-CXCR7 axis was systematically evaluated in tumor and stromal cells, through rigorous statistical methods in a prospective clinical trial. CXCL12 expression in cancer cells is associated with worse progression-free survival in stage III EOC patients, and deserves further attention as a potential prognostic and therapeutic target. This study investigated the prognostic role of the CXCR4-CXCL12-CXCR7 axis in advanced epithelial ovarian cancer (EOC) patients receiving first-line treatment within the MITO16A/MaNGO-OV2 phase-IV trial. CXCR4-CXCL12-CXCR7 expression was evaluated in the epithelial and stromal component of 308 EOC IHC-stained tumor samples. The statistical analysis focused on biomarkers' expression, their association with other variables and prognostic value. Zero-inflated tests, shrinkage, bootstrap procedures, and multivariable models were applied. The majority of EOC (75.0%) expressed CXCR4 and CXCR7, 56.5% expressed the entire CXCR4-CXCL12-CXCR7 axis, while only 4.6% were negative for CXCL12 and its cognate receptors, in regard to the epithelial component. Stromal CXCL12 and CXCR7, expressed in 11.2% and 65.5%, respectively, were associated with the FIGO stage. High CXCL12 in epithelial cancer cells was associated with shorter progression-free and overall survival. However, after adjusting for overfitting due to best cut-off multiplicity testing, the significance was lost. This is a wide-ranging, prospective study in which CXCR4-CXCL12-CXCR7 were systematically evaluated in epithelial and stromal components, in selected stage III-IV EOC. Although CXCL12 was not prognostic, epithelial expression identified high-risk FIGO stage III patients for PFS. These data suggest that it might be worth studying the CXCL12 axis as a therapeutic target to improve treatment efficacy in EOC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study
- Author
-
von Arx, Claudia, primary, Rea, Giuseppina, additional, Napolitano, Maria, additional, Ottaiano, Alessandro, additional, Tatangelo, Fabiana, additional, Izzo, Francesco, additional, Petrillo, Antonella, additional, Clemente, Ottavia, additional, Di Sarno, Antonella, additional, Botti, Gerardo, additional, Scala, Stefania, additional, and Tafuto, Salvatore, additional
- Published
- 2020
- Full Text
- View/download PDF
5. New CXCR4 Antagonist Peptide R (Pep R) Improves Standard Therapy in Colorectal Cancer
- Author
-
D’Alterio, Crescenzo, primary, Zannetti, Antonella, additional, Trotta, Anna Maria, additional, Ieranò, Caterina, additional, Napolitano, Maria, additional, Rea, Giuseppina, additional, Greco, Adelaide, additional, Maiolino, Piera, additional, Albanese, Sandra, additional, Scognamiglio, Giosuè, additional, Tatangelo, Fabiana, additional, Tafuto, Salvatore, additional, Portella, Luigi, additional, Santagata, Sara, additional, Nasti, Guglielmo, additional, Ottaiano, Alessandro, additional, Pacelli, Roberto, additional, Delrio, Paolo, additional, Botti, Gerardo, additional, and Scala, Stefania, additional
- Published
- 2020
- Full Text
- View/download PDF
6. New CXCR4 Antagonist Peptide R (Pep R) Improves Standard Therapy in Colorectal Cancer.
- Author
-
D'Alterio, Crescenzo, Zannetti, Antonella, Trotta, Anna Maria, Ieranò, Caterina, Napolitano, Maria, Rea, Giuseppina, Greco, Adelaide, Maiolino, Piera, Albanese, Sandra, Scognamiglio, Giosuè, Tatangelo, Fabiana, Tafuto, Salvatore, Portella, Luigi, Santagata, Sara, Nasti, Guglielmo, Ottaiano, Alessandro, Pacelli, Roberto, Delrio, Paolo, Botti, Gerardo, and Scala, Stefania
- Subjects
ANIMAL experimentation ,ANTINEOPLASTIC agents ,CANCER chemotherapy ,CELL lines ,CELL receptors ,COLON tumors ,FLUOROURACIL ,GENE expression ,MICE ,PEPTIDES ,RECTUM tumors ,XENOGRAFTS ,OXALIPLATIN ,TREATMENT effectiveness ,CHEMICAL inhibitors ,PHARMACODYNAMICS - Abstract
The chemokine receptor CXCR4 is overexpressed and functional in colorectal cancer. To investigate the role of CXCR4 antagonism in potentiating colon cancer standard therapy, the new peptide CXCR4 antagonist Peptide R (Pep R) was employed. Human colon cancer HCT116 xenograft-bearing mice were treated with chemotherapeutic agents (CT) 5-Fluorouracil (5FU) and oxaliplatin (OX) or 5FU and radio chemotherapy (RT-CT) in the presence of Pep R. After two weeks, CT plus Pep R reduced by 4-fold the relative tumor volume (RTV) as compared to 2- and 1.6-fold reductions induced, respectively, by CT and Pep R. In vitro Pep R addition to CT/RT-CT impaired HCT116 cell growth and further reduced HCT116 and HT29 clonal capability. Thus, the hypothesis that Pep R could target the epithelial mesenchyme transition (EMT) process was evaluated. While CT decreased ECAD and increased ZEB-1 and CD90 expression, the addition of Pep R restored the pretreatment expression. In HCT116 and HT29 cells, CT/RT-CT induced a population of CD133+CXCR4+ cells, supposedly a stem-resistant cancer cell population, while Pep R reduced it. Taken together, the results showed that targeting CXCR4 ameliorates the effect of treatment in colon cancer through inhibition of cell growth and reversal of EMT treatment-induced markers, supporting further clinical studies. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. New CXCR4 Antagonist Peptide R (Pep R) Improves Standard Therapy in Colorectal Cancer
- Author
-
Salvatore Tafuto, Maria Napolitano, Anna Maria Trotta, Alessandro Ottaiano, Giosuè Scognamiglio, Guglielmo Nasti, Luigi Portella, Roberto Pacelli, Sandra Albanese, Caterina Ieranò, Paolo Delrio, Sara Santagata, Antonella Zannetti, Giuseppina Rea, Piera Maiolino, Fabiana Tatangelo, Gerardo Botti, Crescenzo D'Alterio, Adelaide Greco, Stefania Scala, D'Alterio, Crescenzo, Zannetti, Antonella, Trotta Anna, Maria, Ierano, Caterina, Napolitano, Maria, Rea, Giuseppina, Greco, Adelaide, Maiolino, Piera, Albanese, Sandra, Scognamiglio, Giosue, Tatangelo, Fabiana, Tafuto, Salvatore, Portella, Luigi, Santagata, Sara, Nasti, Guglielmo, Ottaiano, Alessandro, Pacelli, Roberto, Delrio, Paolo, Botti, Gerardo, and Scala, Stefania
- Subjects
Cancer Research ,Colorectal cancer ,medicine.medical_treatment ,EMT epithelial-to-mesenchymal transition ,Population ,education ,colorectal cancer ,CXCL12 axi ,chemotherapy ,CXCR4 ,lcsh:RC254-282 ,Article ,CXCR4/CXCL12 axis ,Medicine ,radiotherapy ,CXCL12 axis ,education.field_of_study ,Chemotherapy ,CXCR4 antagonist ,business.industry ,Cell growth ,chemoresistance ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,digestive system diseases ,Oxaliplatin ,Oncology ,Cancer cell ,Cancer research ,cardiovascular system ,business ,medicine.drug - Abstract
The chemokine receptor CXCR4 is overexpressed and functional in colorectal cancer. To investigate the role of CXCR4 antagonism in potentiating colon cancer standard therapy, the new peptide CXCR4 antagonist Peptide R (Pep R) was employed. Human colon cancer HCT116 xenograft-bearing mice were treated with chemotherapeutic agents (CT) 5-Fluorouracil (5FU) and oxaliplatin (OX) or 5FU and radio chemotherapy (RT-CT) in the presence of Pep R. After two weeks, CT plus Pep R reduced by 4-fold the relative tumor volume (RTV) as compared to 2- and 1.6-fold reductions induced, respectively, by CT and Pep R. In vitro Pep R addition to CT/RT-CT impaired HCT116 cell growth and further reduced HCT116 and HT29 clonal capability. Thus, the hypothesis that Pep R could target the epithelial mesenchyme transition (EMT) process was evaluated. While CT decreased ECAD and increased ZEB-1 and CD90 expression, the addition of Pep R restored the pretreatment expression. In HCT116 and HT29 cells, CT/RT-CT induced a population of CD133+CXCR4+ cells, supposedly a stem-resistant cancer cell population, while Pep R reduced it. Taken together, the results showed that targeting CXCR4 ameliorates the effect of treatment in colon cancer through inhibition of cell growth and reversal of EMT treatment-induced markers, supporting further clinical studies.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.